Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elamipretide - Stealth BioTherapeutics

Drug Profile

Elamipretide - Stealth BioTherapeutics

Alternative Names: Bendavia; ELA 4; Elamipretide-hydrochloride; Elamipretide-hydrochloride - Stealth Biotherapeutics; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31

Latest Information Update: 26 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Institut de recherches cliniques de Montreal
  • Developer Stealth BioTherapeutics
  • Class Amides; Antihyperglycaemics; Eye disorder therapies; Heart failure therapies; Neuroprotectants; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Cardiolipin modulators; Free radical scavengers; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies; Leber's hereditary optic atrophy; Barth syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Barth syndrome
  • Phase III Mitochondrial myopathies
  • Phase II Acute kidney injury; Corneal disorders; Dry age-related macular degeneration; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Reperfusion injury
  • Phase I/II Diabetic macular oedema
  • Preclinical Friedreich's ataxia
  • No development reported Chronic heart failure; Diabetes mellitus; Eye disorders; Neurodegenerative disorders

Most Recent Events

  • 25 Aug 2021 Stealth BioTherapeutics has patent protection for elamipretide for the treatment of Barth syndrome and Barth syndrome-related cardiomyopathy in USA
  • 24 Aug 2021 Preregistration for Barth syndrome (In adolescents, In children, In the elderly, In adults) in USA (SC)
  • 24 Aug 2021 Stealth BioTherapeutics files NDA to the US FDA for Barth syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top